After Illumina CEO’s Fall, Other Executives Are Expected to Take Hard Look at Deals
[ad_1] Share Listen (2 min) [ad_2] Source link
ILMN
Read More
WSJ News Exclusive | Farallon Capital to Wage Proxy Battle at Biotech Firm
[ad_1] WSJ News Exclusive Finance Farallon has nominated three directors to the board of Exelixis [ad_2] Source link
FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer Grail
[ad_1] The agency said the combination would hurt competition for cancer-detection tests while raising prices. [ad_2] Source link